IP Verse

Jiangsu Hengrui Medicine competitive analysis

Latest patents of Jiangsu Hengrui Medicine opposed by its competitors

Explore Jiangsu Hengrui Medicine's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3093295
May 27, 2020Il-15 Heterogeneous Dimer Protein And Uses Thereof1
EP2436684
Mar 4, 2015Salts Of Methyl (R)-7-[3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyryl]-3-Trifluoromethyl-5,6,7,8-Tetrahydro-Imidazo[1,5-A]Pyrazine-1-Carboxylate1
EP2402342
Aug 6, 2014Pharmaceutical Composition For Treatment Of 2 Type Dabetes1

Latest PTAB cases involving Jiangsu Hengrui Medicine

Discover the latest PTAB cases involving Jiangsu Hengrui Medicine, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Jiangsu Hengrui Medicine with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
JIANGSU HENGRUI MEDICINE - 3 - -
GENERICS UK319 - - -
GENERICS UK TRADING MYLAN48 - - -
MARGARET DIXON65 - - -